Cue Biopharma

The head and neck squamous cell carcinoma market is projected to grow at a compound annual growth rate of 10.5% during the 2026–2036 forecast period, driven by the launch of emerging novel immunotherapies. The market size across the seven major markets—the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan—was estimated at USD 850 million in 2025, with the United States accounting for the largest share. Key therapies in development include Amivantamab from Johnson & Johnson, BNT113 from BioNTech, CUE-101 from Cue Biopharma, Petosemtamab from Genmab, and Eftilagimod Alfa from Immutep, among others. The total incident cases of head and neck squamous cell carcinoma in the seven major markets were approximately 153,500 in 2025. Growth is further supported by rising cancer incidence, increasing adoption of immunotherapies and targeted therapies, and a robust pipeline of investigational drugs.

Several biotech stocks reached 52-week highs on July 10, 2026, driven by regulatory updates and quarterly results. American Well Corporation hit $10.16, closing at $9.91, after a Nature report validated its SilverCloud platform and it facilitated a DarioHealth insurer agreement, though full-year 2026 revenue is expected at $195 million to $205 million, below 2025's $249.3 million. Cue Biopharma reached $45.50 and announced a roughly $50 million private placement, while advancing CUE-221 in a Phase 2 allergy study and planning an IND for CUE-401. ImmuCell climbed to $11.59 after reporting unaudited second-quarter sales of $7.2 million, an 11.5% year-over-year increase, with $4.9 million from Tri-Shield First Defense. Scholar Rock hit $58.49, up 3.33%, as its BLA for Apitegromab in SMA is under FDA review with a decision expected by September 30, 2026. Faeth Therapeutics touched $36.89, advancing the PIKTOR combination therapy in a Phase 1/2 breast cancer trial with interim data due in 2027 and a Phase 2 endometrial cancer trial with topline data expected in the second half of 2026.

Cue Biopharma has entered into a securities purchase agreement for a private placement expected to generate gross proceeds of approximately $50 million. The company will sell 1,418,071 shares of common stock at $33.21 per share, and certain investors will receive pre-funded warrants to purchase up to 87,500 shares at $33.209 per warrant. The pre-funded warrants have an exercise price of $0.001 per share and are immediately exercisable. The private placement is led by Cormorant Asset Management with participation from Columbia Threadneedle Investments and is expected to close on or about July 13, 2026, subject to customary closing conditions. Cue Biopharma intends to use the net proceeds to advance clinical development and for general corporate purposes, and it highlighted upcoming data from a Phase 2 study of CUE-221 in chronic spontaneous urticaria expected by the end of the third quarter of 2026.